Founding Organizations

   
   

Founding Individuals

Norman Chen
Partner, Healthcare
Fidelity Asia Ventures

Mr. Norman Chen has over 18 years of experience as a senior executive, entrepreneur and venture capitalist in the healthcare industry in Asia.

He began his healthcare career in 1991 at Baxter International, where he was responsible for the dialysis products business unit across 13 markets in Asia. Based on this experience, Mr. Chen founded Asia Renal Care (ARC) in 1996 with investment from Fidelity Asia Ventures, Investor AB, Walden International and Satellite Dialysis Centers, a non-profit dialysis group based in the San Francisco Bay Area and affiliated with Stanford University.

As CEO and Vice-Chairman, Mr. Chen led ARC’s growth over the next 10 years to become the leading independent dialysis provider in Asia with over 70 dialysis centers in Taiwan, Singapore, Philippines, Japan, Korea and Malaysia. ARC was acquired in 2007 by Bumrungrad International.

In 2002, Mr. Chen joined Walden International as Entrepreneur-in-Residence. In 2005, he joined Fidelity Asia Ventures as their Healthcare Partner for China.

Mr. Chen has a Bachelor of Science degree in Biology from MIT and an MBA from Stanford University. He has lived in Hong Kong since 1992.

 

Dr. Frank Kung
Managing Partner
Vivo Ventures

Dr. Kung is a founding member of Vivo Ventures, LLC (formerly BioAsia Investments), a healthcare/biotechnology venture capital management firm in Palo Alto, California.

Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan.

Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. He received the Best Use of Technology Award from the Governor of California, the Entrepreneur of the Year Awards from Ernst and Young, and the Asian Business League. He also served on the board of directors of the Emerging Company Governing Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science and Technology Association, West Coast; and the Asian American Manufacturing Association. He was appointed by the U.S. Secretary of Health and Human Services as a voting member of the National Biotechnology Policy Board. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.

 

James Li, M.D.
Partner
Kleiner Perkins Caufield & Byers

Dr. James Li joins KPCB China Fund in Oct 2009 to focus on fund’s life science practice. His main investment interests are in the space of bio-pharmaceuticals, vaccines, diagnostics and personalized medicine enabling tools, research services, medical devices and other life science opportunities in China.

James is also a member of Kleiner Perkins Caufield & Byers Pandemic Fund in which his interests are in the areas of the management of emerging infectious disease, specifically in bird flu and swine flu’s rapid diagnosis, prevention and treatment.

Prior to joining KPCB, James spent over 15 years with Merck Co. & Inc. where he held leadership positions with increasing responsibilities in clinical research, regulatory affairs, new product development and franchise management, both in the US and Asia Pacific/China. During his tenure, he was instrumental in obtaining regulatory approvals of Merck vaccines accross Asia Pacific Region when the Vaccine Division started operations in the region, successfully built the foundations of Merck’s medical operations in China and drove the success of Merck’s largest product franchise in Asia.

James received his Medical Degree from Shanghai Medical University, completing an internship in Internal Medicine and a rotation in Oncology, followed by a Master of Science degree in Microbiology from the University of Montana.

James is currently involved with the following companies: BioCryst, GenScript, Kang Hui, Nexus Diagnostics, and Novavax.

 

Hongbo Lu, Ph.D.
Principal
Piper Jaffray

Hongbo Lu is a principal and senior research analyst focusing on China life sciences and healthcare companies. Prior to assuming the China healthcare coverage, Lu was a research analyst at Piper Jaffray covering U.S. biotechnology universe. Prior to joining Piper Jaffray, Lu spent five years in industry as a strategic planning manager and consultant for a number of start-up, biotech, and medical devices companies. Lu has an MBA from UC Berkeley and a Ph.D. in Biomedical Engineering from University of Washington. She is also an honored graduate from Tsinghua University in China.

 

Marietta Wu
General Manager, Greater China
Burrill & Company

Dr. Wu’s experience ranges from clinical medicine and medical research to finance and entrepreneurship. In her current role at Burrill & Company, she focuses on venture capital investing in China and Taiwan related life sciences opportunities. She also serves as an interim COO of Waterstone Pharmaceuticals, a US based pharmaceutical and API manufacturer with key operations in China. In addition, she assists companies seeking trans-Pacific partnerships. Dr. Wu is a frequent speaker and author on China life sciences topics.

Prior to joining Burrill, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company. In the past few years, She has been active in cross border ventures and value creation in the life sciences industry.

Dr. Wu received her M.D. from Shanghai Second Medical University, a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Business School.

Organizing Committee

Norman Chen Partner, Healthcare Fidelity Asia Ventures	Dr. Frank Kung Managing Partner Vivo Ventures	James Li, M.D. Partner Kleiner Perkins Caufield & Byers
Hongbo Lu, Ph.D. Principal Piper Jaffray	Marietta Wu General Manager, Greater China Burrill & Company

 

Leon Chen
Partner
Fidelity Asia Ventures

Leon Chen joined Fidelity Asia Ventures in 2008 with over 15 years of experience as an accomplished scientist, management consultant and venture capitalist.

Prior to joining FAV, Leon was a Managing Partner at BioVeda China and had led a number of investments in the life science sector in China including Cathay Industrial Biotechnology and CITIC Pharmaceuticals.

From 1997 to 2005, Leon was a management consultant and a business adviser to Pharmaceutical and Biotech companies. He worked as a management consultant with McKinsey & Company, Ernst & Young LLP, and as a co-founder and Managing Partner with Life Science Strategic Consulting in the San Francisco Bay Area.

From 1993 to 1997, Leon worked as a research scientist at Schering-Plough in New Jersey. He was a member of the discovery team of "VYTORIN"/"ZETIA" – now a multibillion dollar drug.

He received a BS degree from Peking University, a Ph.D. degree with top honor in Organic Chemistry from Catholic University of Louvain, and was a Post-Doc Fellow at the Massachusetts Institute of Technology. Leon holds 6 issued US Patents and co-authored the 14th and 15th Ernst & Young Biotechnology Report.

 

Jon E. Liong
Managing Partner
Lychee Group

Jon is the founder and owner of Lychee Group, a media company focused on creating high-end events for China's life sciences industry.

Jon brings over 10 years of success in the strategic planning, organization and marketing of pharmaceutical and biotech business-to-business conferences. In 1999, he joined Strategic Research Institute, a leading New York-based conference company. During his tenure there he organized and directed over 100 successful life sciences conferences and managed the production of over 40 events annually. As Managing Director, Jon led the company’s global expansion into Asia, conceiving and launching the "IMPACT CHINA: Pharmaceutical Global R&D" series, which was the first-ever Western-organized conference covering China's life sciences industry.

In 2007, Jon joined Burrill Life Sciences Media Group, the media arm of Burrill & Company, a leading life sciences venture capital firm based in San Francisco. As Director of Events, he was in charge of production and strategic planning to launch new events in the US and China.

Jon received his B.S. in Marketing from the New York University Stern School of Business.

 

Jonathan C. Wang

Jonathan C. Wang is a MBA student at the Wharton Business School majoring in Healthcare Management. During his MBA summer, Jonathan worked as a summer associate at Burrill & Company’s Venture Capital team where he reviewed business plans for investment and advised on portfolio company’s strategies. Prior to Wharton, Jonathan had experience in management consulting with the Boston Consulting Group in their Beijing and Sydney offices.